Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

GSK exercises option for codevelopment of HGS-ETR1

Aug. 30, 2005

Canadian approval for phase III study of Multikine in head and neck cancer

Aug. 25, 2005

MT-103 deemed safe and effective in studies with chimpanzees

Aug. 23, 2005

Serono inlicenses worldwide rights to Genmab's HuMax-CD4

Aug. 22, 2005

sBLA filing for Rituxan

Aug. 22, 2005

Promising preliminary results for HER-2 Protein AutoVac in breast cancer

Aug. 18, 2005

CT-011 shows promise in the management of advanced hematological malignancies

Aug. 10, 2005

Fast track designation for panitumumab for metastatic colorectal cancer

Aug. 4, 2005

GTC Biotherapeutics and Scancell collaborate on SC-101

Aug. 2, 2005

GCAN-101 begins phase II study for metastatic cancers

Aug. 1, 2005

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...